FDA Approves Gamifant as First Treatment for MAS in Still’s Disease
Sobi announced that the U.S. Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with…
Read More...
Read More...
